Fluidigm (NASDAQ:FLDM) Trading Up 7.9%

Fluidigm Co. (NASDAQ:FLDM)’s share price was up 7.9% during trading on Wednesday . The stock traded as high as $2.67 and last traded at $2.58, approximately 764,600 shares changed hands during mid-day trading. A decline of 15% from the average daily volume of 896,074 shares. The stock had previously closed at $2.39.

Several equities research analysts have commented on FLDM shares. Janney Montgomery Scott downgraded Fluidigm from a “buy” rating to a “neutral” rating in a report on Wednesday, November 6th. UBS Group raised Fluidigm from a “neutral” rating to a “buy” rating and dropped their target price for the stock from $14.00 to $7.00 in a report on Friday, October 18th. BidaskClub raised Fluidigm from a “sell” rating to a “hold” rating in a report on Saturday, November 2nd. Finally, Zacks Investment Research downgraded Fluidigm from a “hold” rating to a “sell” rating in a report on Monday, November 11th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $10.81.

The company has a quick ratio of 2.44, a current ratio of 2.89 and a debt-to-equity ratio of 0.33. The company has a fifty day simple moving average of $3.50 and a 200 day simple moving average of $7.61. The firm has a market capitalization of $175.30 million, a P/E ratio of -3.23 and a beta of 2.11.

Fluidigm (NASDAQ:FLDM) last released its earnings results on Tuesday, November 5th. The medical research company reported ($0.19) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.20) by $0.01. The business had revenue of $26.50 million for the quarter, compared to the consensus estimate of $28.74 million. Fluidigm had a negative return on equity of 25.11% and a negative net margin of 57.10%. The company’s revenue for the quarter was down 8.5% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.13) earnings per share. As a group, equities analysts expect that Fluidigm Co. will post -0.6 earnings per share for the current fiscal year.

In other news, insider Levin Easterly Partners Llc sold 11,545 shares of the company’s stock in a transaction on Wednesday, September 11th. The stock was sold at an average price of $5.55, for a total transaction of $64,074.75. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 2.00% of the company’s stock.

Several large investors have recently made changes to their positions in FLDM. BlackRock Inc. lifted its holdings in shares of Fluidigm by 86.5% during the second quarter. BlackRock Inc. now owns 4,943,298 shares of the medical research company’s stock valued at $60,902,000 after purchasing an additional 2,293,024 shares in the last quarter. FMR LLC bought a new position in shares of Fluidigm during the first quarter valued at $24,188,000. Vanguard Group Inc. lifted its holdings in shares of Fluidigm by 84.1% during the second quarter. Vanguard Group Inc. now owns 3,746,808 shares of the medical research company’s stock valued at $46,160,000 after purchasing an additional 1,711,187 shares in the last quarter. Nuveen Asset Management LLC bought a new position in shares of Fluidigm during the second quarter valued at $13,875,000. Finally, Allianz Asset Management GmbH lifted its holdings in Fluidigm by 146.6% in the second quarter. Allianz Asset Management GmbH now owns 1,030,722 shares of the medical research company’s stock valued at $12,698,000 after acquiring an additional 612,774 shares during the period. 90.99% of the stock is currently owned by hedge funds and other institutional investors.

Fluidigm Company Profile (NASDAQ:FLDM)

Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios, a CyTOF system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents and Maxpar human immune monitoring panel kit and workflow.

Recommended Story: The role of implied volatility with call option volume

Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.